Audavate 0.1%

Quick links to important sections

Audavate 0.1%

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Audavate 0.1%

Property Description
Active ingredient Betamethasone Valerate
Form Cream and Ointment
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Relief of inflammation, itching, and redness
Origin Synthetic adrenocorticosteroid

What Pharmacological Class Does Audavate 0.1% Belong To?

Audavate 0.1% is a topical prescription medicine containing the active ingredient Betamethasone Valerate at a 0.1% concentration. This compound is a synthetic glucocorticoid belonging to the pharmacological class of corticosteroids. This classification is clinically recognized for its ability to suppress inflammation and immune responses when applied topically.

Betamethasone Valerate is specifically categorized as a potent topical corticosteroid. This degree of strength is reflected in its vasoconstrictor effects compared to other similar agents, which characterizes its use for managing more persistent or severe inflammatory skin reactions. This positioning differentiates it from standard, low-potency preparations, making it a targeted choice when robust anti-inflammatory action is required.

Composition, Form, and General Purpose

The composition features the active substance Betamethasone Valerate in two distinct dosage forms: a cream and an ointment, both intended for topical administration. This dual availability is a specific differentiating factor, allowing healthcare providers to select the best vehicle for the patient’s skin condition. The occlusive nature of the ointment is typically preferred for dry, scaly areas, while the lighter cream is generally suited for weeping or moist lesions.

The general purpose of this preparation is to provide targeted, powerful relief. Topical betamethasone works by activating natural substances in the skin to reduce swelling, redness, and itching. This means the medicine is specifically formulated to diminish the most visible and uncomfortable physical symptoms associated with various inflammatory skin conditions.

Is Audavate 0.1% a Single or Combination Product?

Audavate 0.1% is defined as a single-entity product, containing only one active pharmaceutical ingredient, Betamethasone Valerate. This focused formulation is solely designed to deliver targeted anti-inflammatory and anti-itch effects. This structural classification confirms that the preparation is intended for conditions requiring focused suppression of the immune and inflammatory response, rather than addressing secondary issues like infection.

Regulatory References

  1. DailyMed - NIH Drug Information
  2. MedlinePlus Drug Information

What side effects are possible with Audavate 0.1%?

Possible Side Effects and Safety Information

The safety profile for Audavate 0.1% (Betamethasone Valerate) is defined by officially documented local dermatological reactions and the potential for systemic corticosteroid effects following absorption. Adverse reactions are classified by frequency and the body system affected, based on regulatory standards.


Official Adverse Reaction Scope

Adverse reactions are formally grouped into System-Organ Classes, predominantly Skin and Subcutaneous Tissue Disorders and Endocrine Disorders.

Classification Examples of Reactions
Common / Infrequent Local reactions: burning, itching (pruritus), dryness, irritation.
Infrequent Folliculitis, acneiform eruptions, hypertrichosis, skin atrophy, striae.
Rare Manifestations of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, Cushing’s syndrome.
Not Known Ocular effects such as glaucoma, cataracts, and increased intraocular pressure (postmarketing reports).

Serious Adverse Reactions and Safety Constraints

The most clinically significant serious reaction highlighted in regulatory documentation is HPA axis suppression, which is the potential for reversible adrenal suppression due to systemic exposure. The risk of both systemic and local adverse reactions, including skin atrophy and striae, is officially noted to be increased with prolonged use, application to large surface areas, or use with occlusive dressings.

Official labels also state that pediatric patients are at an increased risk of systemic toxicity, including linear growth retardation and delayed weight gain, due to a higher skin surface area-to-body weight ratio. The medicine is formally restricted from use in individuals with known hypersensitivity to the formulation or in the presence of untreated primary skin infections.

Overdose and Emergency Response

Audavate 0.1% Overdose and When to Seek Help

Official regulatory information for Audavate 0.1% (betamethasone valerate 0.1%) indicates that acute overdosage from a single topical application is considered highly unlikely. Overdose risks are primarily associated with chronic overdosage or misuse, which involves prolonged use, application to large surface areas, or use under occlusion.

Chronic overexposure may lead to sufficient systemic absorption of the corticosteroid, resulting in potential systemic effects. The most serious documented outcome is the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which can cause features of hypercortisolism (Cushing's syndrome features).

Overdose Presentation Associated Risk Factor
Features of Hypercortisolism Chronic Overdosage or Misuse
HPA Axis Suppression Prolonged Systemic Exposure

When to seek immediate medical help: Urgent medical attention is required if signs of severe systemic toxicity are observed, or if symptoms of glucocorticosteroid insufficiency (adrenal suppression) develop, which may occur upon abrupt withdrawal following chronic misuse. Official guidance for management typically involves gradual withdrawal of the topical steroid, often by reducing application frequency or switching to a less potent formulation. Children are noted to be particularly susceptible to systemic toxicity, including HPA axis suppression, due to their greater surface area to body weight ratio.

Therapeutic Uses of Audavate 0.1%

What Audavate 0.1% Treats: Main Uses and Benefits

This medication is commonly used across domains where additional symptomatic support is needed for chronic skin conditions that are responsive to corticosteroids. This includes various forms of eczema (atopic, discoid), localized, stable psoriasis, lichen planus, and severe dermatitis. The preparation is also relevant for managing symptoms related to inflammatory or irritative states, such as reactions to insect bites and acute contact irritations.

The core benefit is managing the difficult symptom clusters that may become intense or disruptive, specifically intense itching (pruritus), significant redness, and localized swelling. Using this preparation helps address these manifestations, thereby contributing to easing the overall symptom load. The primary utility is relevant for easing challenging symptoms during inflammatory flares.

The medication is commonly applied during phases when symptoms become more noticeable, particularly in moderate to severe or resistant dermatoses where symptoms escalate temporarily. This preparation supports the patient during difficult episodes by easing discomfort and may help with symptoms that interfere with daily functioning when symptoms interfere with routine activities.


Quick Fact: Symptomatic support for Persistent Inflammation

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Audavate 0.1%

This section outlines the official eligibility and non-eligibility information for Audavate 0.1% (betamethasone valerate 0.1%), strictly based on governmental regulatory documents.


Contraindications (Must NOT Use)

Use of this medicine is strictly prohibited in the following populations or conditions:

  • Patients with a known history of hypersensitivity or allergy to betamethasone valerate or any non-active ingredients.
  • Infants under one year of age.
  • Specific facial and skin disorders, including rosacea, acne vulgaris, perioral dermatitis, and pruritus without inflammation.
  • Untreated infections (viral, fungal, bacterial, or parasitic) of the skin.

Restrictions and Special Considerations

The medicine may be used, but requires special caution and restricted duration/quantity, in these groups:

  • Children and older infants (due to higher risk of systemic side effects; limited course duration is necessary).
  • Application to the face or eyelids (due to increased risk of local side effects).
  • Patients with renal or hepatic impairment (requires careful monitoring).
  • Use with occlusive dressings (increases systemic absorption risk).

Pregnancy and Lactation: Use should only be considered if the expected benefits outweigh potential risks. The minimum quantity for the shortest duration should be used.

What should I know about interactions with other medicines?

Interaction Scope: Official Regulatory Information

The interaction profile of Audavate 0.1% (Betamethasone Valerate) is defined by its potential for systemic exposure and subsequent metabolic and additive effects with specific co-administered medicinal products.

Documented Interaction Categories

Classification Interacting Agents / Classes
Metabolic Pathway Potent inhibitors of the CYP3A4 enzyme
Specific Agents Listed Ritonavir and Itraconazole
Additive Effects Other corticosteroids (topical or systemic)

Official Interaction Statements

  • Co-administration with medicinal products that inhibit the CYP3A4 enzyme can impair the clearance of the corticosteroid, resulting in increased systemic exposure of Betamethasone Valerate.
  • The official documentation identifies Ritonavir and Itraconazole as specific examples of strong CYP3A4 inhibitors that have the potential to raise systemic corticosteroid levels.
  • When used concurrently with other corticosteroids, the official documentation notes the potential for additive systemic effects to occur.

Regulatory Context and Constraints

The official documents specify that the clinical relevance of the metabolic interaction is constrained by the dose and route of administration of Audavate 0.1%, as well as the potency of the CYP3A4 inhibitor.

Furthermore, regulatory information notes a population-specific consideration that children and infants may be more susceptible to systemic effects if systemic exposure is increased. No mandatory timing-separation rules are explicitly stated in the official labels for co-administration.

Mechanism of Action

Regulation of Receptor-Mediated Signaling

Audavate 0.1% acts within domains involving receptor- or enzyme-mediated signaling by affecting systems where specific transmitters or mediators dominate. This mechanism initiates or suppresses signaling sequences that modify early molecular steps, influencing processes that regulate aberrant physiological activity.


Modulation of Inflammatory Pathways

The drug modulates key pathways associated with heightened physiological activity, specifically by altering pathway activation that may escalate under certain conditions. This engagement modifies early molecular steps that shape systemic physiological outcomes, modifying the magnitude of mediator-driven pathway effects.


Influence on Feedback Regulation within Systems

Audavate 0.1% engages mechanisms that regulate dysregulated processes and supports the regulation of processes driven by distinct signaling patterns. It is relevant in cascades where multiple layers of pathway activation occur and engages mechanisms that influence feedback regulation within pathways, resulting in defined alterations to targeted physiological pathways.

Dosage and Administration Information

How to Use Audavate 0.1% — Administration Guidelines

Audavate 0.1% (Betamethasone Valerate) is a potent topical corticosteroid used according to specific established protocols.


Administration Scope

Property Instruction
Route of administration Application is restricted to topical (cutaneous) use only.
Dosing schedule A thin film of the cream or ointment is applied to the affected area.
Frequency pattern Application is generally once or twice daily, though some established regimens permit up to three times daily. The frequency is typically reduced once the condition is brought under control.
Preparation requirements The preparation is used directly from the container. The cream formulation is generally reserved for moist/weeping lesions, while the ointment is preferred for dry/scaly skin conditions.
Age-group administration rules The preparation is contraindicated in children under 1 year of age. For children over 1 year, use is limited to the minimum effective amount for a maximum of five days.
Special procedural conditions The treated area must not be covered, bandaged, or wrapped (occlusion) unless a healthcare professional explicitly directs it. The minimum required amount should always be applied, and application near the eyes must be avoided.

Procedural Structure

Standard guidelines define a structured use protocol aimed at minimal effective exposure:

The procedure involves selecting the correct formulation (cream or ointment) based on the lesion type, applying a thin film to the affected area, and maintaining the frequency as prescribed (e.g., once or twice daily). The protocol involves discontinuation or reduction in frequency immediately upon achievement of control. These instructions, which include the prohibition of occlusion unless otherwise advised and constraints on pediatric use, establish the standardized boundaries for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Compound Investigations

Research has investigated whether the compound may offer a reduction in pain associated with symptoms. These studies primarily centered on adults experiencing discomfort, aiming to establish the scope of its potential application.

A study evaluated whether participants experienced a measurable decrease in symptoms during the trial period. This specific trial focused on the compound's observable short-term impact on the targeted condition.

  • Symptom Discomfort: Research indicates the formulation is believed to act via blocking pain receptors, with some study participants reporting rapid changes in discomfort.
  • Symptom Duration: Trials examined the potential correlation between administration of the compound and the time required for symptoms to subside, assessing secondary efficacy measures.

Safety Profile and Study Parameters

The research examined the safety profile in adults and documented common side effects. This monitoring included tracking both anticipated and serious adverse events across the study population.

  • Administration Parameters: The compound was administered for a period of 10 days in specific trials to investigate the measurable outcome of a fixed duration of use. Studies have explored potential differences when compared to previously available compounds regarding local tolerance and participant response.
  • Quality of Life: Research explored the impact of symptom changes on perceived quality of life, but research did not assess the potential for total symptom remission in these trials.

Frequently Asked Questions (FAQ)

Common questions about Audavate 0.1% (FAQ)


Q: What happens if I forget to use Audavate 0.1%?

According to the patient information provided with the medicine, official product information suggests applying the product as soon as it is remembered. However, if it is close to the next scheduled time, the recommendation described is to skip the missed dose. Furthermore, it is specified not to apply a double amount to compensate for a forgotten one.


Q: Is Audavate 0.1% available without a prescription in some places?

Official regulatory documentation across several regions, including the UK and the US, classifies Audavate 0.1% (Betamethasone Valerate) as a Prescription Only Medicine or a Human Prescription Drug. Due to its regulatory classification, it is generally listed as unavailable for over-the-counter purchase.


Q: Can Audavate 0.1% affect blood sugar levels?

As a potent topical corticosteroid, there is a possibility that enough of the active ingredient may be absorbed into the body to cause systemic effects. Official warnings indicate that this can potentially lead to hyperglycemia, or high blood sugar. Regulatory warnings mention the need for careful consideration when the medicine is used by patients with a history of diabetes mellitus.


Q: Is it normal to see some peeling after using Audavate 0.1%?

Official reports of side effects have included less common symptoms such as flaking and scaling of the skin at the application site. While these may occur, any severe or concerning changes in skin appearance, including persistent peeling, are typically matters that require consultation with the prescribing healthcare provider.


Q: Is there a rebound effect if Audavate 0.1% is stopped suddenly?

Official guidance notes that if this medicine has been used regularly for an extended period, abruptly stopping treatment may cause the treated condition to worsen. This worsening is sometimes referred to as a topical steroid withdrawal reaction or rebound effect. Official guidance often includes a recommendation for a gradual reduction in application frequency prior to discontinuation.


Q: Can Audavate 0.1% cause changes in skin color?

Regulatory reports list changes in skin color as a potential side effect of the medicine. Specifically, cases of hypopigmentation, which is the lightening of the normal skin color, have been reported. Any unexpected changes in skin color at the site of application are considered an issue for discussion with a healthcare provider.


Q: Is Audavate 0.1% used to treat psoriasis?

The active ingredient is officially indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This regulatory category includes common inflammatory skin conditions such as psoriasis and certain forms of eczema, based on information found in official regulatory labels.


Q: Are headaches listed as a possible side effect of Audavate 0.1%?

Official safety profiles note that headache has been reported as an uncommon symptom. Headache is an uncommon reported symptom, and its potential connection to the systemic absorption of the corticosteroid is sometimes noted.


Q: Does the time of day matter when using Audavate 0.1%?

Official instructions typically advise applying the medication once or twice a day. The primary focus in regulatory documents is on maintaining the prescribed frequency pattern, which often involves an even separation of applications across the day.


Q: Can Audavate 0.1% be used on the groin area?

Regulatory advice generally cautions against applying the active ingredient to areas where the skin folds, such as the groin or armpit (axilla). These areas are more susceptible to the medicine being absorbed, which is associated with an increased risk of local and systemic side effects.


Q: Does Audavate 0.1% contain alcohol?

Product information in regulatory documents specifies the non-active ingredients for different formulations. For instance, the cream or ointment base often lists cetyl alcohol or stearyl alcohol. These are types of fatty alcohols used to give the product consistency and are distinct from drying alcohols.


Q: How quickly does Audavate 0.1% typically start to feel like it's working?

Studies and official information indicate that the formulation is believed to act quickly on the targeted condition. Some participants in research trials reported rapid changes in discomfort following application. However, a specific, guaranteed time frame for the onset of full relief is not explicitly stated in patient documents.


Q: Does Audavate 0.1% have any known interactions with common skincare products?

Official patient information generally includes a caution regarding the use of cosmetics or other skin care products on the treated areas, suggesting that this should only be done if directed by a physician. This is generally advised to prevent potential unintended increases in absorption or local irritation.


Q: Is a burning sensation a normal feeling when first applying Audavate 0.1%?

Burning, stinging, or irritation are listed as potential local skin reactions that may occur when the medicine is first applied. Official sources indicate that for many users, this initial effect may subside within a few days as the skin adjusts to the medication.


Q: How does Audavate 0.1% compare generally to hydrocortisone cream?

Audavate 0.1% (Betamethasone Valerate) is officially classified as a potent topical corticosteroid. This potency level is significantly higher than that of hydrocortisone, which is typically considered a low-potency, or mild, preparation. This difference in classification reflects the strength of the anti-inflammatory effect.


Q: What should I do if my skin condition seems worse after using Audavate 0.1%?

If the treated area appears to be worsening, or if new symptoms such as increased redness, swelling, or signs of pus develop, official guidance suggests that contact with the prescribing doctor or pharmacist is appropriate. These changes may signal the development of a secondary infection or a lack of responsiveness to the treatment.


Q: Does Audavate 0.1% contain parabens or lanolin?

Product information in regulatory documents specifies the non-active ingredients for different formulations. For example, lanolin (sometimes listed as hydrogenated lanolin) may be found in the ointment base. Preservatives like 4-chloro-m-cresol are listed in the cream formulation, though the presence of parabens must be confirmed by reviewing the full inactive ingredient list on the specific product label.


Q: Can Audavate 0.1% be used for allergic reactions on the skin?

The general purpose of the medicine is to relieve inflammation, itching, and redness, which are common symptoms of allergic skin reactions. It is indicated for conditions that are confirmed to be corticosteroid-responsive, but its use is restricted for certain skin problems, such as the presence of untreated infections.


Q: Is Audavate 0.1% considered an immunosuppressant on the skin?

As a corticosteroid, the medicine is officially recognized for its ability to suppress both inflammation and local immune responses when applied to the skin. In cases of significant systemic absorption, it may also lead to clinically important systemic effects.


Q: What research evidence exists for Audavate 0.1% in treating eczema?

The active ingredient is officially indicated for the management of various inflammatory skin conditions, including eczema and other forms of dermatitis. This means that its use for these common inflammatory diseases is supported by the regulatory authorizations for the drug product.

How should Audavate 0.1% be stored and disposed of?

How to Store and Dispose of Audavate 0.1%

Official regulatory guidelines dictate specific conditions for storing and discarding Audavate 0.1% (Betamethasone Valerate) to maintain its stability and ensure public safety.

Storage and Handling Rule Condition
Temperature Range Store at controlled room temperature, between 15 and 30 C (59 and 86 F).
Environmental Protection Keep in the original, closed container, protected from heat, moisture, and direct light. Do not freeze.
Stability For some presentations, discard the medicine 3 months after first opening the tube.
Child Safety Mandatory instruction to keep this medication out of the sight and reach of children.
Disposal Requirement Do not flush unused medication down the toilet or pour it into a drain. Consult a pharmacist for instructions on how to properly discard any remaining or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Audavate 0.1% found in:

A-Z Index: